$Eli Lilly(LLY.US)
Context: Eli Lilly has had a strong run, gaining about 30% since March as investors remain optimistic about its diabetes and obesity drug business. The stock has also recently reached new highs.
My trade: I closed my position last night after the strong rally. Rather than chase the stock higher, I’m happy to lock in the gains.
Takeaway: I know Lilly remains a strong growth story but expectations are also high. Also, pharma stocks face risks from drug pricing pressure, competition, regulation, and the uncertainty of developing new treatments.
2026.02.03 ~ 2026.08.19 All orders
Cumulative P/L294.99 (USD)+30%
2026.02.032026.08.19
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.